ABL1 is altered in 0.7% of mature T-cell and NK-cell neoplasm patients [2].

ABL1 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain ABL1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

AFF1 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain AFF1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

ASXL1 is altered in 2.82% of mature T-cell and NK-cell neoplasm patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BCR is altered in 1.33% of mature T-cell and NK-cell neoplasm patients [2].

BCR is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain BCR status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

DEK is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain DEK status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

ELL is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain ELL status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

FLT3 is altered in 1.64% of mature T-cell and NK-cell neoplasm patients [2].

FLT3 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

IKZF1 is altered in 1.44% of mature T-cell and NK-cell neoplasm patients [2].

IKZF1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains IKZF1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (0 open) [3].

KMT2A is altered in 3.28% of mature T-cell and NK-cell neoplasm patients [2].

KMT2A is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

MECOM is altered in 4.96% of mature T-cell and NK-cell neoplasm patients [2].

MECOM is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

MLF1 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MLF1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

MLLT1 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MLLT1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MLLT10 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MLLT3 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MLLT4 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

NPM1 is altered in 1.17% of mature T-cell and NK-cell neoplasm patients [2].

NPM1 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain NPM1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

NRIP3 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain NRIP3 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

NUP214 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain NUP214 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

PBX1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains PBX1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (0 open) [3].

RPN1 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain RPN1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

RUNX1 is altered in 0.94% of mature T-cell and NK-cell neoplasm patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TCF3 is altered in 1.09% of mature T-cell and NK-cell neoplasm patients [2].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for mature T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (0 open) [3].

TP53 is altered in 12.27% of mature T-cell and NK-cell neoplasm patients [2].

TP53 is an inclusion eligibility criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].